Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Transformed Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes
PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
PROCEDURE: Myeloablative Conditioning

Sponsor

City of Hope Medical Center

Collaborators

[object Object]